Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 1
Opinion
Video
Therapeutic Combination Therapies for Metastatic Prostate Cancer
Author(s):
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic prostate cancer patients, with treatment selection influenced by factors such as disease volume and risk level.
Video Player is loading.
The above content is prompted by the following:
- Discuss some therapeutic combinations for metastatic prostate cancer.
- What is the general rationale for using combination therapy (eg, androgen receptor–targeted agent and/or an androgen deprivation therapy with docetaxel)?
- How do disease volume and level of disease risk affect selection of therapy?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
The ADVANCED-2 trial, TARA-002
Unmet needs in high risk NMIBC
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
The Current Landscape of ADT in Prostate Cancer
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
Related Content
